<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Drug Alcohol Depend</journal-id><journal-id journal-id-type="iso-abbrev">Drug Alcohol Depend</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Drug and alcohol dependence</journal-title></journal-title-group><issn pub-type="ppub">0376-8716</issn><issn pub-type="epub">1879-0046</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10041683</article-id><article-id pub-id-type="pmcid-ver">PMC10041683.1</article-id><article-id pub-id-type="pmcaid">10041683</article-id><article-id pub-id-type="pmcaiid">10041683</article-id><article-id pub-id-type="manuscript-id">NIHMS1881735</article-id><article-id pub-id-type="pmid">34974270</article-id><article-id pub-id-type="doi">10.1016/j.drugalcdep.2021.109236</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1881735</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1881735</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Impact of transitioning from long-term to intermittent opioid therapy on the development of opioid-related adverse outcomes: A retrospective cohort study</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Hayes</surname><given-names initials="CJ">Corey J.</given-names></name><xref rid="A1" ref-type="aff">a</xref><xref rid="A2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Krebs</surname><given-names initials="EE">Erin E.</given-names></name><xref rid="A3" ref-type="aff">c</xref><xref rid="A4" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Brown</surname><given-names initials="J">Joshua</given-names></name><xref rid="A5" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="C">Chenghui</given-names></name><xref rid="A6" ref-type="aff">f</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hudson</surname><given-names initials="T">Teresa</given-names></name><xref rid="A1" ref-type="aff">a</xref><xref rid="A2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Martin</surname><given-names initials="BC">Bradley C.</given-names></name><xref rid="A6" ref-type="aff">f</xref><xref rid="CR1" ref-type="corresp">*</xref></contrib></contrib-group><aff id="A1"><label>a</label>Department of Biomedical Informatics, College of Medicine, University of Arkansas for Medical Sciences, 4301 West Markham Street, Slot 782, Little Rock, AR 72205, USA</aff><aff id="A2"><label>b</label>Center for Mental Healthcare and Outcomes Research, Central Arkansas Veterans Healthcare System, 2200 Fort Roots Drive, Bldg. 58, North Little Rock, AR 72114, USA</aff><aff id="A3"><label>c</label>Center for Care Delivery and Outcomes Research, Minneapolis VA Healthcare System, 1 Veterans Drive, Minneapolis, MN 55417, USA</aff><aff id="A4"><label>d</label>Department of Medicine, University of Minnesota Medical School, 401 East River Parkway, VCRC 1st Floor, Suite 131, Minneapolis 55455, USA</aff><aff id="A5"><label>e</label>Center for Drug Evaluation and Safety, Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, 1225 Center Drive, HPNP #3334, Gainesville, FL 32610, USA</aff><aff id="A6"><label>f</label>Division of Pharmaceutical Evaluation and Policy, College of Pharmacy, University of Arkansas for Medical Sciences, 4301 West Markham Street, Slot 522, Little Rock, AR 72205, USA</aff><author-notes><corresp id="CR1"><label>*</label>Corresponding author. <email>bmartin@uams.edu</email> (B.C. Martin).</corresp><fn fn-type="COI-statement" id="FN1"><p id="P37">Conflicts of Interest</p><p id="P38">Dr. Martin receives royalties from TrestleTree LLC for the commercialization of an opioid risk prediction tool, which is unrelated to the current study. Drs. Martin and Li are paid consultants for eMaxHealth Systems for unrelated projects. The remaining authors have no conflicts of interest to disclose.</p></fn></author-notes><pub-date pub-type="ppub"><day>01</day><month>2</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>24</day><month>12</month><year>2021</year></pub-date><volume>231</volume><issue-id pub-id-type="pmc-issue-id">432056</issue-id><fpage>109236</fpage><lpage>109236</lpage><pub-history><event event-type="nihms-submitted"><date><day>21</day><month>03</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>27</day><month>03</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>27</day><month>03</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-15 05:25:25.783"><day>15</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1881735.pdf"/><abstract id="ABS1"><sec id="S1"><title>Background:</title><p id="P1">Increasing pressures exist to reduce or discontinue opioid use among patients currently on long-term opioid therapy (LTOT). It is essential to understand the potential effects of opioid reduction.</p></sec><sec id="S2"><title>Methods:</title><p id="P2">This retrospective cohort study was conducted among veterans with chronic pain and on LTOT. Using 1:1 propensity score-matched samples of veterans switching to intermittent opioid therapy and those continuing LTOT, we examined the development of subsequent substance use disorders (SUD composite; individual SUD types: opioid, non-opioid drug, and alcohol use disorders) and opioid-related adverse outcomes (ORAO composite; individual ORAO types: accidents resulting in wounds/injuries, opioid-related and alcohol/non-opioid medication-related accidents and overdoses, self-inflicted and violence-related injuries). Sensitivity analyses were conducted using logistic regression with stabilized inverse probability of treatment weighting (SIPTW) and instrumental variable (IV) models.</p></sec><sec id="S3"><title>Results:</title><p id="P3">A total of 29,293 veterans switching to intermittent therapy were matched to veterans continuing LTOT. With matched samples, no differences were found in composite SUDs and OR AOs between the groups. With SIPTW, veterans switching to intermittent opioid therapy had higher odds of composite SUDs and ORAOs (SUDs aOR=1.12, 95%CI: 1.07,1.17; ORAOs aOR=1.05, 95%CI:1.00,1.09). IV models found lower risks for composite SUDs and ORAOs among veterans switching to intermittent opioid therapy (SUDs: &#946; = &#8722;0.38, 95%CI:&#8722;0.63,&#8722;0.13; ORAOs: &#946; = &#8722;0.27, 95%CI:&#8722;0.50,&#8722;0.04).</p></sec><sec id="S4"><title>Conclusions:</title><p id="P4">There were no consistent associations between transitioning patients from LTOT to intermittent opioid therapy and the risk of SUDs and ORAOs.</p></sec></abstract><kwd-group><kwd>Opioids</kwd><kwd>Long-term opioid therapy</kwd><kwd>Chronic non-cancer pain</kwd><kwd>Intermittent opioid therapy</kwd><kwd>Opioid-related adverse outcomes</kwd><kwd>Substance use disorders</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>